Core Insights - Harmony Biosciences announced positive results from its pivotal bioequivalence study for pitolisant gastro-resistant formulation, indicating its potential as a next-generation treatment for narcolepsy [1][2] - The company plans to submit a New Drug Application (NDA) in early 2026, targeting a PDUFA date in Q1 2027, with utility patent applications filed for exclusivity until 2044 [1][3] Bioequivalence Study Results - The pivotal bioequivalence study confirmed that 17.8mg of pitolisant gastro-resistant is bioequivalent to existing 17.8mg WAKIX tablets, with AUC and Cmax ratios of 108.46% and 99.65% respectively [2] - No new safety or tolerability issues were reported, and 100% of patients successfully initiated treatment at the therapeutic dose without the need for titration [2] Market Position and Future Developments - The progress on pitolisant gastro-resistant formulation highlights the accelerating momentum of the pitolisant franchise, which is nearing blockbuster status in narcolepsy [3] - Harmony is also developing pitolisant HD, a high-dose formulation aimed at enhancing efficacy for excessive daytime sleepiness and other symptoms in narcolepsy and idiopathic hypersomnia [3] Company Overview - Harmony Biosciences is focused on developing innovative therapies for rare neurological diseases, emphasizing a commitment to patients with unmet medical needs [19]

Core Viewpoint - Poxel SA is implementing a recovery plan to stabilize its financial situation and avoid liquidation, with new management focused on cost control and business development [3][5][6]. Recovery Plan Update - The recovery plan has been finalized, emphasizing commercial development for Imeglimine, PXL 770, and PXL 065, alongside significant cost reductions and clearing of liabilities [4][5]. - New financing commitments of up to €11.25 million from financial partners IPF and IRIS are aimed at supporting the recovery efforts [5][7]. - The plan requires approval from the Commercial Court of Lyon and will be presented to shareholders at the annual general meeting on December 11, 2025 [5][11]. Financial Structure and Capital Transactions - The recovery plan includes a capital increase with preferential subscription rights for existing shareholders, expected to be at a discount of 30% to 50% of the current share price [12][26]. - A capital increase reserved for IPF will be at a premium of 5% to 10% compared to the preferential subscription rights price [12][26]. - The restructuring aims to ensure that IPF retains approximately 29.9% of the company's share capital post-transaction [17][24]. Management and Strategic Focus - The new management team has been actively working since August to streamline operations and focus on core business areas, including potential partnerships for Imeglimine in Asia [6][9]. - The company plans to reduce administrative costs by transferring its listing to Euronext Growth, which will lower regulatory expenses [10][12]. Shareholder Engagement - A webinar is scheduled for November 26, 2025, to discuss the recovery plan and future prospects with shareholders [5][32]. - Shareholders will have the opportunity to vote on the proposed financial delegations and capital transactions during the upcoming general meeting [11][12].

Market Performance - The Tel Aviv Stock Exchange experienced a decline, with the Tel Aviv 35 Index falling by 1.15% to 3,320.72 points, and the Tel Aviv 125 Index decreasing by 1.20% to 3,359.47 points. The BlueTech Global Index also dropped by 1.36% to 574.59 points [1] - The All Bond corporate bond index saw a slight increase of 0.09% to 419.78 points. Total turnover in equities was NIS 1.54 billion, while bond turnover reached NIS 1.97 billion [1] Currency Exchange Rates - The shekel-dollar exchange rate was set 0.644% higher at NIS 3.28/$, and the shekel-euro rate increased by 0.834% to NIS 3.784/€ [2] Notable Stock Movements - Nice (Nasdaq: NICE; TASE: NICE) recorded the largest gain on the Tel Aviv 35 Index, rising by 4.60%. Other banks such as Bank Hapoalim (TASE: POLI), Mizrahi Tefahot Bank, Israel Discount Bank (TASE: DSCT), and First International Bank of Israel (TASE: FTIN1; FTIN5) also saw modest increases [2] - Conversely, Bank Leumi (TASE: LUMI) led the market decline with a drop of 0.51%. Tower Semiconductor Ltd. (Nasdaq: TSEM; TASE: TSEM) experienced the largest fall on the Tel Aviv 35 Index, decreasing by 8.37%. Other notable declines included Camtek (Nasdaq: CAMT; TASE: CAMT) down 5.22%, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) down 1.53%, Elbit Systems Ltd. (Nasdaq: ESLT; TASE: ESLT) down 3.40%, and Delek Group (TASE: DELKG) down 4.32% [3]

Core Insights - The conference highlights the growth opportunities for the company, particularly in high-value components critical to the supply chain for injectable drugs, which is one of the fastest-growing segments in the pharmaceutical pipeline [2][3] - The company is experiencing strong secular tailwinds, including growth in GLP-1s and compliance with Annex 1 regulations, which are expected to drive future growth [2] - The company maintains a strong competitive position as the market leader in primary containment and elastomers, providing a significant competitive moat [3] Company Overview - The company has recently welcomed a new Chief Financial Officer, indicating a potential shift or enhancement in financial strategy [2] - The leadership team expresses excitement about the company's prospects and the opportunities presented at the investment conference [2] Industry Context - The pharmaceutical industry is witnessing rapid growth in the injectable drug segment, which is a key focus area for the company [2] - The demand for high-value components is expected to increase, driven by the overall growth in the pharmaceutical pipeline [2]

Pharmaceutical chain Big Caring is considering an initial public offering in Kuala Lumpur next year, according to people familiar with the matter https://t.co/Pa6h8eTd3H ...

Company Performance - Home Depot's stock fell 6%, marking the worst performance in the S&P 500, after the company missed third-quarter earnings forecasts and lowered its full-year profit outlook due to a lack of storms and economic uncertainty affecting homeowner remodeling projects [4][9]. - Medtronic's stock rose approximately 5% after exceeding analysts' estimates for fiscal second-quarter sales and adjusted profit, driven by strong demand in its end markets [8][10]. Market Overview - Major U.S. equity indexes declined for the second consecutive day, with the S&P 500 dropping 0.8%, the Dow sliding 1.1%, and the Nasdaq losing 1.2%, ahead of several high-profile earnings reports and delayed jobs data [3]. - Concerns regarding high valuations in the artificial intelligence sector negatively impacted tech stocks, with Western Digital and Micron Technology shares falling 5.9% and 5.6%, respectively [5]. Regulatory Developments - Amazon and Microsoft shares decreased by 4.4% and 2.7%, respectively, following the announcement of investigations by European Union regulators into their cloud computing services [6].

Core Points - Bristol Myers Squibb has announced the accepted amounts and pricing terms for its tender offers to purchase outstanding notes, adjusting the maximum aggregate purchase prices for both Pool 1 and Pool 2 Notes [1][2][10] Group 1: Tender Offer Details - The maximum aggregate purchase price for Pool 1 Notes has been decreased to approximately $3.99 billion, while the maximum for Pool 2 Notes has been increased to approximately $3.51 billion [2][10] - All validly tendered Pool 1 Notes and Pool 2 Notes with acceptance priority levels 1 through 4 have been accepted for purchase, eliminating the need for proration procedures for these notes [4][10] - The 2033 Notes will be accepted on a prorated basis due to the total principal amount exceeding $250 million [4][10] Group 2: Financial Terms - The Total Consideration for each series of Notes accepted for purchase will be paid in cash, excluding accrued and unpaid interest up to the Early Settlement Date [11][12] - The Offers will expire on December 3, 2025, unless extended or terminated earlier, with the Early Settlement Date set for November 20, 2025 [10][11] Group 3: Participation and Acceptance - The withdrawal rights for the Offers expired on November 17, 2025, and all conditions of the Offers were satisfied or waived by the Early Tender Deadline [10][11] - Holders of Notes that are accepted for purchase will receive the applicable Total Consideration, while those not accepted will have their notes returned promptly [4][11]

Core Points - Bristol Myers Squibb announced early participation results for its tender offers to purchase outstanding notes, with changes to the maximum aggregate purchase prices for both Pool 1 and Pool 2 Notes [1][9] - The company has decreased the maximum purchase price for Pool 1 Notes from $4 billion to an amount sufficient to accept all validly tendered notes, while increasing the maximum for Pool 2 Notes from $3 billion to accommodate all validly tendered notes with priority levels 1 through 4, plus up to $250 million of 5.900% Notes due 2033 [1][8] - The early settlement date for the offers is set for November 20, 2025, with the offers expiring on December 3, 2025, unless extended [9][10] Pool 1 Notes Summary - The total principal amount of Pool 1 Notes validly tendered by the early tender deadline includes $360 million of 4.950% Notes due 2026, $529.9 million of 3.200% Notes due 2026, $519.5 million of 4.900% Notes due 2027, and $560.1 million of 4.900% Notes due 2028 [5][8] - Bristol Myers Squibb does not anticipate accepting any additional tenders of Pool 1 Notes after the early tender deadline due to the maximum purchase price being met [8] Pool 2 Notes Summary - The total principal amount of Pool 2 Notes validly tendered includes $6.2 million of 6.875% Debenture due 2097, $879.2 million of 6.400% Notes due 2063, $811.5 million of 6.250% Notes due 2053, and $1.3 billion of 5.650% Notes due 2064 [7][8] - No Pool 2 Notes with acceptance priority levels 6 through 9 will be accepted for purchase [8] Additional Information - All accepted notes will be cancelled and retired, ceasing to be outstanding obligations of Bristol Myers Squibb [11] - Holders of accepted notes will receive cash payments for accrued and unpaid interest in addition to their total consideration [10]

Core Insights - Vida Ventures has achieved its fourth major portfolio acquisition in 2025, marking a record-setting year for the firm with a focus on a science-led and disciplined investment strategy [2][4]. Acquisition Highlights - Halda Therapeutics was acquired by Johnson & Johnson for $3.05 billion, representing the largest acquisition ever for a Phase 1 stage company across any therapeutic area [3][6]. - Eli Lilly acquired Scorpion Therapeutics for up to $2.5 billion, enhancing its oncology portfolio with a next-generation targeted therapy platform [4][6]. - Sanofi completed its acquisition of Vigil Neuroscience for an upfront payment of $470 million, with potential contingent value rights (CVR) up to $600 million, focusing on a first-in-class TREM2 agonist for Alzheimer's disease [4][6]. - AbbVie acquired Capstan Therapeutics for a record-breaking $2.1 billion, the highest upfront payment for a company with only healthy-volunteer data [4][6]. Investment Strategy - Vida's multi-pillar investment strategy combines deep scientific expertise, disciplined capital deployment, and engagement at multiple entry points across the life sciences landscape [5][8]. - The firm focuses on recognizing differentiated mechanisms early and supporting them with technical rigor to scale value through clinical and strategic inflection points [5][8]. Future Outlook - Vida Ventures enters 2026 with strong momentum and a diversified portfolio, poised for continued clinical progress as the biotech sector becomes more data-driven and capital-efficient [8].

The appetite for weight-loss drugs has been insatiable since they hit the market a decade ago. As pharmaceutical firms elbow each other for a slice of the pie, the buffet of options will grow in 2026 https://t.co/9RjiPe583n ...